Pharmaceutical Technology

MAY 25, 2023

ElevateBio has raised $401m in a Series D financing round for advancing its technology platforms to expedite the design, production and development of cell and gene therapies. The technology platforms include the Life Edit gene editing platform, an RNA, cell, protein, vector engineering and induced pluripotent stem cells (iPSCs) platform.

Gene Therapy 243

Gene Therapy Gene Gene Editing Manufacturing 243

Drug Discovery World

SEPTEMBER 25, 2023

CRISPR gene editing companies Integrated DNA Technologies (IDT) and Aldevron have inked a new global distribution agreement to expand CRISPR products for cell and gene therapy customers.

Genome 52

Genome Genomics Gene Editing Medicine 52

Pharmaceutical Technology

NOVEMBER 16, 2022

A custom-made viral vector and cell therapy centre of excellence, ElevateBio BaseCamp has an end-to-end process development and existing Good Manufacturing Practice (cGMP) production expertise for research, clinical and commercial cell and gene therapies and regenerative treatments.

Development 246

Development Gene Therapy Engineer Gene Editing 246

pharmaphorum

JUNE 23, 2022

Novartis has shouldered its way into the in vivo gene editing category via a deal with US biotech Precision BioSciences, focused on a therapy for sickle cell disease (SCD). It is also working with Eli Lilly on in vivo gene-editing drugs against three targets, including one in Duchenne muscular dystrophy, under the terms of a $1.4

Gene Editing 97

Gene Editing In-Vivo Gene Sequencing Gene 97

Drug Discovery World

MAY 24, 2023

Touchlight, a company providing DNA services and manufacturing enzymes, has completed the redevelopment and expansion of its UK manufacturing facility in London, UK. The expanded facility’s manufacturing capacity has tripled and is now capable of producing more than 8kg a year.

DNA 52

DNA Gene Editing Gene Therapy Genetics 52

pharmaphorum

APRIL 23, 2021

CRISPR Therapeutics is to receive a hefty $900m payment from Vertex after the companies amended a collaboration to develop, manufacture and market a gene editing therapy for sickle cell disease and beta thalassemia.

Gene Editing 64

Gene Editing Gene DNA Bacteria 64

Pharmaceutical Technology

AUGUST 26, 2022

ElevateBio has signed a long-term strategic collaboration with the University of Pittsburgh, US, to establish a biomanufacturing centre for expediting cell and gene therapy development.

Gene Therapy 162

Gene Therapy Gene Editing Gene Manufacturing 162

Drug Discovery World

MAY 9, 2024

Mekonos, a company working towards cell engineering on a chip, has entered into a partnership agreement with Accelerated Bio to codevelop a new manufacturing cell line based on Accelerated Bio’s human Trophoblast Stem Cells (hTSCs) and Gene Engineered Multi-Sites (GEMS) technology.

Engineer 64

Engineer Gene Editing Manufacturing Gene 64

Drug Discovery World

DECEMBER 8, 2023

The companies’ R&D teams will collaboratively evaluate ONK’s gene-edited NK cell therapy, ONKT105, with NAYA’s NY-303 bispecific antibody before selecting the best candidates for potential clinical development. Both companies will share the costs of manufacturing and preclinical assessments.

Antibody 52

Antibody Gene Editing Clinical Trials Clinical Trials 52

pharmaphorum

MAY 7, 2021

Gene editing firm CRISPR Therapeutics has announced a collaboration with US biotech Nkarta to develop natural killer (NK) cell therapies for cancer. It’s at the forefront of gene editing although the technology has spawned rivals including Intellia Therapeutics, Caribou Biosciences, Sangamo Therapeutics and Mammoth Biosciences.

Gene Editing 52

Gene Editing Gene Genetic Engineering DNA 52

Drug Discovery World

JUNE 7, 2023

The disease-relevant mutation is engineered into bit.bio’s human ioWild Type  cells using CRISPR/Cas9 gene editing. This enables the manufacture of any human cell type at scale with precision and consistency, making the models suited to screening applications for early drug discovery as well as for fundamental research.

Gene Editing 52

Gene Editing Scientist Gene Engineer 52

The Pharma Data

JUNE 7, 2023

Bayer strengthens gene therapy portfolio with lipid nanoparticle technology from Acuitas Therapeutics Bayer AG is joining forces with Acuitas Therapeutics, Inc., “Accessing state-of-the-art LNP technology through this collaboration will add momentum to our gene editing efforts for the benefit of patients.”

Gene Therapy 40

Gene Therapy Gene Gene Editing In-Vivo 40

Drug Discovery World

JUNE 22, 2023

Evox Therapeutics has purchased Codiak Biosciences engEx-AAV technology platform, including all intellectual property rights, and exclusive access to certain engineering and manufacturing rights. The post Evox Therapeutics acquires exosome AAV technology from Codiak appeared first on Drug Discovery World (DDW).

Gene Therapy 52

Gene Therapy Gene Editing Drug Delivery Gene 52

The Pharma Data

JANUARY 17, 2021

18, 2021 /PRNewswire/ — Aruvant Sciences, a private company focused on developing gene therapies for rare diseases, and Lonza announced today their agreement in support of ARU-1801, Aruvant’s one-time investigational gene therapy for sickle cell disease (SCD). NEW YORK , Jan.

Manufacturing 52

Manufacturing Gene Therapy Trials Gene 52

Pharmaceutical Technology

MARCH 1, 2023

It discovers, develops and manufactures prescription drugs to treat cancer, multiple sclerosis and infertility; and develops liquid crystal mixtures, organic light-emitting diode (OLED) materials, cosmetic active ingredients, pigments for coatings, and high-tech materials.

Gene Editing 100

Gene Editing DNA Cosmetics Life Science 100

Pharmaceutical Technology

MARCH 1, 2023

It discovers, develops and manufactures prescription drugs to treat cancer, multiple sclerosis and infertility; and develops liquid crystal mixtures, organic light-emitting diode (OLED) materials, cosmetic active ingredients, pigments for coatings, and high-tech materials.

Gene Editing 100

Gene Editing DNA Cosmetics Life Science 100

Drug Discovery World

SEPTEMBER 6, 2022

As we look to the future, many advanced therapy players are sticking to traditional cell and gene technologies like autologous cell therapies and gene therapy using adeno-associated viral vectors, but some are branching out to other models like allogeneic cell therapies, non-viral delivery methods and gene-editing technologies.

Gene Therapy 52

Gene Therapy Gene Gene Editing Manufacturing 52

Pharmaceutical Technology

JUNE 15, 2023

Verve Therapeutics and Eli Lilly and Company have entered an exclusive research partnership to advance the former’s preclinical stage in vivo gene editing programme targeting lipoprotein(a) (Lp(a)) to treat atherosclerotic cardiovascular disease (ASCVD).

Gene Editing 130

Gene Editing Gene Gene Therapy In-Vivo 130

pharmaphorum

SEPTEMBER 29, 2020

For example, under a traditional pharma/biotech collaboration and licensing model, a biotech partner may have primary responsibility for significant elements of research and early product development, and the pharma partner may lead the majority of later stage development, as well as post-approval commercial manufacture and supply.

Research 132

Research Gene Editing Gene Development 132

Drug Discovery World

AUGUST 11, 2023

Dr Shang Xiaoyun, CEO of T-MAXIMUM, said: “Gene editing reagents are crucial raw materials for the quality and efficacy of our products. T-MAXIMUM Biotech hopes to progress multiple products to the Phase II clinical research stage and deliver products to market within the next five years.

Reagent 52

Reagent Development Gene Editing Production 52

pharmaphorum

OCTOBER 21, 2020

The financing will support manufacturing of a first clinical batch of the product, regulatory activities and a first human study scheduled to start next year. Boissel was previously executive vice president of corporate strategy at gene editing biotech Sangamo Therapeutics.

Gene Therapy 98

Gene Therapy Gene Gene Editing Genetics 98

Drug Discovery World

NOVEMBER 27, 2023

Upstream cell line development has seen notable progress with recent advances in cell line engineering, particularly in enhancing gene of interest integration specificity, clone selection, and production efficiency. Next-generation engineering tools, such as gene editing have enabled knock-out cell lines with enhanced characteristics.

Production 59

Production Engineer Gene Editing Gene 59

The Pharma Data

AUGUST 4, 2020

UK-based Oxford Biomedica has signed a new development, manufacture and license agreement with Beam Therapeutics for next-generation CAR-T therapeutics. Agreement will utilise Oxford Biomedica's LentiVector platform. The agreement also puts in place a three year clinical supply agreement for the two companies.

Gene Editing 52

Gene Editing Licensing Licensing Clinical Supply 52

pharmaphorum

AUGUST 25, 2022

Explore approaches to boost safe gene-editing, approach regulatory affairs, turbocharge scale-up, optimize analytics and more to produce best-in-class therapies for immuno-oncology and regenerative medicine. Sana Biotechnology , Takeda and many more.

Gene Editing 40

Gene Editing Genome Genomics Engineer 40

Drug Discovery World

DECEMBER 11, 2023

The US Food and Drug Administration (FDA) has approved the first cell-based gene therapies for the treatment of sickle cell disease (SCD), Casgevy and Lyfgenia. Casgevy, from Vertex Pharmaceuticals and CRISPR Therapeutics, is also the first FDA-approved treatment to use CRISPR gene editing technology.

Gene Therapy 52

Gene Therapy FDA Approval Gene Gene Editing 52

pharmaphorum

DECEMBER 21, 2022

As part of the acquisition, Kite will assume responsibility for continuing the R&D collaboration between Tmunity and Penn, which includes options and licenses to cell engineering and manufacturing technologies invented and developed in the university’s laboratories. Image by Anja from Pixabay .

Gene Editing 52

Gene Editing Licensing Licensing Manufacturing 52

Drug Discovery World

JULY 18, 2023

The centre also features a newly built demo lab which will bring the Revvity portfolio closer to scientists.

Genome 52

Genome Genomics Life Science Gene Editing 52

Cloudbyz

MARCH 6, 2024

This shift signifies not just a change in the way drugs are manufactured and administered, but also a fundamental transformation in the approach to treating diseases at their root cause. In this blog post, we delve into the rise of biologics and explore how they are reshaping the pharmaceutical industry and improving patient outcomes.

Gene 72

Gene Immune Response Manufacturing Gene Therapy 72

Roots Analysis

JANUARY 16, 2023

At-home Self-testing Kit Manufacturers – Current Market Landscape. Gene Editing beyond CRISPR Market, 2022-2035. Cell and Gene Therapy Bioassay Services Market, 2021-2030. Currently, more than 650 at-home self-testing kits are available worldwide and are approved by regulatory authorities. Our Social Media Platform.

Bioassay 52

Bioassay Gene Editing Marketing Gene Therapy 52

Delveinsight

JANUARY 14, 2021

Last year, the company disclosed its gene-writing service, which combined various gene editing, manufacturing, and synthesizing technologies to provide more tailored therapeutic instructions to genetic code. Verve Therapeutics has an aim to bring one-and-done gene editing treatments to heart disease.

Gene Editing 40

Gene Editing Gene Genetics DNA 40

Drug Discovery World

SEPTEMBER 6, 2022

With 2,261 ongoing clinical trials in regenerative medicine, the FDA expects to approve 1 between 10 and 20 new cell and gene therapies a year by 2025. Gene editing and CRISPR technologies are also quickly advancing with many companies heading to the clinic in the next few years.

Gene Therapy 52

Gene Therapy Gene Manufacturing Clinical Trials 52

pharmaphorum

OCTOBER 8, 2021

The company is also seeking if there is evidence of clonal expansion of the abnormality in in other words passed on to daughter cells – and if it is linked to the gene-editing used to modify the ALLO-501A cells.

Trials 52

Trials Gene Editing Genetics Gene 52

The Pharma Data

JANUARY 12, 2021

“There is an incredible unmet need in some diseases that can only be addressed through cell and gene therapies.”. As a result, the company settled on four areas of focus – iPSC, allogenic CAR-T, genome mutations and gene editing. However, she said the company wants to strengthen its position in gene editing.

Gene Therapy 52

Gene Therapy Gene Gene Editing Licensing 52

Drug Discovery World

MAY 23, 2023

White also highlights challenges in the workforce, skill sets, the cost of manufacture and the robustness of supply chains. Beyond 2023, I think we’ll continue to see more innovations driven by improvements in gene editing and biological understanding.” He explains: “We want to enable greater access to patients.

Gene Therapy 52

Gene Therapy Gene Gene Editing Production 52

Advarra

NOVEMBER 29, 2022

Bottlenecks in the manufacturing process, supply chain issues such as accessibility of good manufacturing practice (GMP)-grade reagents, and shortages of qualified scientists and engineers have caused many therapies to fail at critical stages of the clinical development pipeline. But review issues are not the only problems.

Gene Therapy 52

Gene Therapy Gene Production Clinical Trials 52

XTalks

DECEMBER 13, 2023

XTALKS WEBINAR: Cryopreservation Best Practices for Cell & Gene Therapy Source Material Live and On-Demand: Monday, January 22, 2024, at 11am EST (4pm GMT/UK) Register for this free webinar to learn about cryopreservation, a vital step in the manufacturing of today’s cell and gene therapies. How do Casgevy and Lyfgenia Work?

Gene Therapy 98

Gene Therapy FDA Approval Gene In-Vivo 98

Drug Discovery World

DECEMBER 15, 2022

The data observed from the first treated patient support the potential of a trem-cel transplant to be successfully manufactured, to engraft normally, and to maintain blood counts following treatment with the CD33-targeted therapy Mylotarg. x106 CD34+ viable cells/kg, with a CD33 editing efficiency of 88% was manufactured.

Drugs 52

Drugs Genome Genomics Engineer 52